[Problems in the development of a vaccine against schistosomiasis mansoni].
During the last two decades, studies on antigens that may confer protective immunity to experimental infection with Schistosoma mansoni have made great advances, due largely to increased knowledge in the fields of molecular biology and immunology. Although these studies have made new and important contributions, at the present time the degree of protection conferred remains at approximately 50% in reducing the number of flukes and, with some antigens, the number of eggs. The many questions still to be answered indicate the necessity of carrying out further research on small and large animals before these antigen candidates for vaccines can be used in clinical tests.
Katz
N
N
Laboratório de Esquistossomose, Centro de Pesquisas René Rachou, Belo Horizonte, MG, Brasil. nkatz@netra.cpqrr.fiocruz.br
D006801:Humans; D012555:Schistosomiasis mansoni / Q000517:prevention & control*; D014612:Vaccines
D014612:Vaccines